Rua Life Sciences Share Discussion Threads

[spawny100] 30/11/2023 18:25

FFS that stinks - what a nice Xmas present. Sorry for all holders. Glad I didn't believe a word he said and sold out for a profit earlier this week.

[harrogate] 30/11/2023 18:20

Sorry - I see it has happened. I know they needed money but this just shows surely that you can't believe a word that this board says. Interesting that Caroline isn't joining in.

[harrogate] 30/11/2023 18:11

It would not surprise me!

[bones] 30/11/2023 18:02

Placing at 11p £4.8M approx.

Comments on a postcard please...

[joeblogg2] 29/11/2023 13:29

How can that research note be taken seriously or have any credibility with current price!!!

[toffeeman] 29/11/2023 10:45

>> Langland LoL

[langland] 29/11/2023 10:32

So, if we all buy the shares now, we'll make about 23 times our money. Is that how it all works?!

[edmonda] 29/11/2023 10:10

Trading Update - note out from Equity Development here:

RUA released a trading update ahead of its December interim results announcement. In contrast to the previous year, revenues have been weighted to the second half and while this has suppressed first half revenue growth, October’s and November’s revenues have largely caught up to align with management’s budget expectations.

RUA’s recent strategy update and its trading update have several common themes. The reliance on partnerships to fund the development of RUA’s products in RUA Structural Heart and RUA Vascular should reduce R&D and Admin expenditure and conserve cash to provide a pathway for the Group to reach profitability. The continued emphasis on tight resource control is expected to help with this objective.

Our valuation is unchanged at £120.3m or 542p per share.

[cocker] 28/11/2023 18:58

My post below starting to look even more feasible given the share price action.

[blackhorse23] 27/11/2023 08:19

Switching to APH

[cocker] 24/11/2023 17:18

RUA has a spot on TW daily pod cast, subscribers only

[cocker] 24/11/2023 16:51

My post 2652 hit the nail on the head as far as the exclusive deal with Corcym on the 25th Jan 2023. Unfortunately for we investors BB's ego seems more important than his executive decision making. Maybe a cynic would say the strategic update this week was an orchestrated attempt to allow some to exit at a higher price, as there was no reason whatsoever for a TU only two days later

[unionhall] 24/11/2023 14:48

That is exactly what it says Harrogate.

And since they specifically mention broadening it through the industry there is no exclusivity implied.

[bones] 24/11/2023 11:43

I guess we will “shortly”; find out!

[harrogate] 24/11/2023 11:35

I know we all engage in pouring over the words and the semantics. But isn't it possible that the provision of some material to a HV major for THEIR OWN TESTING is just that - no cash involved or a commercial commitment but a fairly long 3rd party lab bench programme to give them the confidence. I have no idea - just throwing it out there for thoughts

[bones] 24/11/2023 11:26

From the strategy update:

”….. The Company expects to shortly formalise an agreement to provide composite material to a large heart valve company for its own testing and now that an attractive data pack is available on the composite, RUA intends to broaden this further through the industry…..221;

How “shortly”; might that be? Implication is perhaps pre-Xmas? Hopefully, there will be a cash element and a sense of continuation and more to come. When will the data pack start to be made available to others? Vital questions.

Looking ahead, even if some parts of heart valve and vascular are farmed out or sold, the rights to the use of Elast-Eon in the products should result in a perpetual and sizeable stream of royalties and fees to RUA Biomaterials which is the holder of that IP.

Historically the original rights to Elast-Eon were acquired for north of £20M when it was just a laboratory tested substance. Since then, it has been used worldwide by Abbott Labs in particular in implantable pacing leads.

Despite RUA’s weak cash position, the need for Elast-Eon in these heart valve materials and the vascular line of grafts could be a trump card if more than one major wants a look at it. That seems likely given the precarious nature of the animal gelatin supply chain being restricted to antipodean cattle herds that could at any given time be struck down with BSE and the like. I understand that the majors consider that risk to be an existential threat to the tissue based industry which is over 80% of the world market. After the Covid pandemic, no one is calling that bluff again.

[drradcliffe] 24/11/2023 11:01

What's interesting is Equity Development weren't expecting a trading update. They seemed to think the 20/11/23 Strategy Update replaced a trading update.

From their note 21/11/23:

"Strategy Update In place of the trading statement which is usually released at this time of year, and ahead of RUA Life Sciences’ interim results, RUA has released a more material - and very well-received - strategy update."

"Sticking to its objectives In place of a trading statement that updates investors on the progress of its revenue-generating businesses and its products in development, RUA’s strategy update has been well-received by investors because it outlines the path of the business to greater and earlier revenues than we had expected in RUA Contract Manufacture and RUA Structural Heart. The strategy also lowers the risks for investors compared to funding the development of RUA’s products solely by an equity offering, at a time where life science markets are depressed and the potential dilution punitive."

Does this mean the market itself wasn't expecting this trading update?

I wonder whether it was a very recent decision to do this in order to stabilise the share price, and specifically on a Friday morning to get rid of the short term traders?

If you are going to arrange a small placing, the last thing you want is a highly volatile share price.

[zen12] 24/11/2023 09:38

They have money coming in now over £1m as per RNS. This is going the right way, no justification for this being taken down today, unless designed to flush out traders.

[zen12] 24/11/2023 09:34

Savage flushing by MMs 0.33-0.27 (20%), traders all out in a flash in time for Fri reporting!

[langland] 24/11/2023 09:32

Based on the known knowns the company does not need to raise. Cash burn is currently running at about 2 thirds of last year's. So, if CM increases as hoped, then cash should stretch for a year possibly longer. As for Harrogate's point this does not preclude the outright sale of the HV business with some royalty thrown in as a kicker. Plenty to speculate about over the next few months.

[zen12] 24/11/2023 09:27

It is highly likely the new business is lot more than potential' but far advanced and happening to fruition..hence confirmation of NO dilution!Remember BoD can't tell you everything, but need to stay reserved..for the just in case scenario.

[bones] 24/11/2023 09:06

The ideal situation (optimist hat on) is a deal with some substance from heart valve material supply, then a raise on the back of that with a purpose related to heart valve business progression.

In the meantime, if someone will kindly take on Vascular…̷0;…..!